Literature DB >> 25398377

Medication overuse headache.

Valerie Cheung1, Farnaz Amoozegar, Esma Dilli.   

Abstract

Medication overuse headache (MOH) is a common and disabling headache disorder. It has a prevalence of about 1-2 % in the general population. The International Classification of Headache Disorders 3rd edition (beta version) has defined MOH as a chronic headache disorder in which the headache occurs on 15 or more days per month due to regular overuse of medication. These headaches must have been present for more than 3 months. The pathophysiology is complex and not completely known. It involves genetic and behavioural factors. There is evidence that cortical spreading depression, trigeminovascular system and neurotransmitters contribute to the pain pathway of MOH. The treatment of MOH includes patient education, stopping the offending drug(s), rescue therapy for withdrawal symptoms and preventative therapy. Relapse rates for MOH are high at 41 %. MOH can severely impact quality of life, so it is important to identify patients who are at risk of analgesic overuse.

Entities:  

Mesh:

Year:  2015        PMID: 25398377     DOI: 10.1007/s11910-014-0509-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  80 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  Medication overuse headache: type I and type II.

Authors:  J R Saper; A E Lake
Journal:  Cephalalgia       Date:  2006-10       Impact factor: 6.292

3.  Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache.

Authors:  Timothy R Smith
Journal:  Headache       Date:  2002-03       Impact factor: 5.887

4.  Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.

Authors:  Chelsea A Meskunas; Stewart J Tepper; Alan M Rapoport; Fred D Sheftell; Marcelo E Bigal
Journal:  Headache       Date:  2006-05       Impact factor: 5.887

Review 5.  Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment.

Authors:  Jacinta L Johnson; Mark R Hutchinson; Desmond B Williams; Paul Rolan
Journal:  Cephalalgia       Date:  2012-11-09       Impact factor: 6.292

6.  Predictive index for the onset of medication overuse headache in migraine patients.

Authors:  T Onaya; M Ishii; H Katoh; S Shimizu; H Kasai; M Kawamura; Y Kiuchi
Journal:  Neurol Sci       Date:  2013-01       Impact factor: 3.307

7.  A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study.

Authors:  C Tassorelli; R Jensen; M Allena; R De Icco; G Sances; Z Katsarava; M Lainez; Ja Leston; R Fadic; S Spadafora; M Pagani; G Nappi
Journal:  Cephalalgia       Date:  2014-02-20       Impact factor: 6.292

8.  Prednisone vs. placebo in withdrawal therapy following medication overuse headache.

Authors:  L Pageler; Z Katsarava; H C Diener; V Limmroth
Journal:  Cephalalgia       Date:  2007-11-26       Impact factor: 6.292

9.  Family history for chronic headache and drug overuse as a risk factor for headache chronification.

Authors:  Sabina Cevoli; Elisa Sancisi; Daniela Grimaldi; Giulia Pierangeli; Stefano Zanigni; Marianna Nicodemo; Pietro Cortelli; Pasquale Montagna
Journal:  Headache       Date:  2009-03       Impact factor: 5.887

10.  Abnormal cortical responses to somatosensory stimulation in medication-overuse headache.

Authors:  Gianluca Coppola; Antonio Currà; Cherubino Di Lorenzo; Vincenzo Parisi; Manuela Gorini; Simona Liliana Sava; Jean Schoenen; Francesco Pierelli
Journal:  BMC Neurol       Date:  2010-12-30       Impact factor: 2.474

View more
  4 in total

1.  Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.

Authors:  Edita Navratilova; Sasan Behravesh; Janice Oyarzo; David W Dodick; Pradeep Banerjee; Frank Porreca
Journal:  Cephalalgia       Date:  2020-07-02       Impact factor: 6.292

2.  Biofeedback in the prophylactic treatment of medication overuse headache: a pilot randomized controlled trial.

Authors:  Marialuisa Rausa; Daniela Palomba; Sabina Cevoli; Luana Lazzerini; Elisa Sancisi; Pietro Cortelli; Giulia Pierangeli
Journal:  J Headache Pain       Date:  2016-09-22       Impact factor: 7.277

3.  Health and quality of life in patients with medication overuse headache syndrome after standardized inpatient rehabilitation: A cross-sectional pilot study.

Authors:  Thomas Benz; Achim Nüssle; Susanne Lehmann; Andreas R Gantenbein; Peter S Sándor; Achim Elfering; André G Aeschlimann; Felix Angst
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

Review 4.  Medication-overuse headache: a widely recognized entity amidst ongoing debate.

Authors:  Nicolas Vandenbussche; Domenico Laterza; Marco Lisicki; Joseph Lloyd; Chiara Lupi; Hannes Tischler; Kati Toom; Fenne Vandervorst; Simone Quintana; Koen Paemeleire; Zaza Katsarava
Journal:  J Headache Pain       Date:  2018-07-13       Impact factor: 7.277

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.